Results 91 to 100 of about 22,609,350 (346)
Biological Landscape of Triple Negative Breast Cancers Expressing CTLA-4
Frontiers in Oncology, 2020 Patients with triple-negative breast cancer (TNBC) have a poor prognosis, partly because of the absence of targeted therapies. Recognition of the key role of immune responses against cancer has allowed the advent of immunotherapy, focused on the ...
María G. C. Navarrete-Bernal +23 more
doaj +1 more source
Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer
Journal of Hematology & OncologyCancer immunotherapies, represented by immune checkpoint inhibitors (ICIs), have reshaped the treatment paradigm for both advanced non-small cell lung cancer and small cell lung cancer. Programmed death receptor-1/programmed death receptor ligand-1 (PD-1/
Weishi Cheng +3 more
semanticscholar +1 more source
Radiotherapy induces responses of lung cancer to CTLA-4 blockade
Nature Medicine, 2018 Focal radiation therapy enhances systemic responses to anti-CTLA-4 antibodies in preclinical studies and in some patients with melanoma1–3, but its efficacy in inducing systemic responses (abscopal responses) against tumors unresponsive to CTLA-4 ...
S. Formenti +17 more
semanticscholar +1 more source
Related Article from Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity
, 2013 Related Article from Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding ...
Holbrook Kohrt (3541958) +2 more
core +1 more source
Reprogramming the Immune Landscape of Inflammatory Breast Cancer
Advanced Science, EarlyView.Inflammatory breast cancer is the most lethal subtype of breast cancer and is characterized by an immunosuppressive tumor microenvironment (TME) driven by a complex network of immune cells and inflammatory cytokines, contributing to its aggressiveness and treatment challenges. Immune checkpoint inhibitors, either alone or in combination, show potential
Verena Martinez‐Rodriguez +3 more
wiley +1 more source
Association of CTLA-4 polymorphisms with hematologic malignancy susceptibility: a meta-analysis
Frontiers in OncologyBackgroundRecent studies have reported an association between Cytotoxic T-lymphocyte antigen-4 (CTLA-4) polymorphisms and hematologic malignancy susceptibility, while the results remain inconsistent. Hence, we performed a meta-analysis to investigate the
Xuefen Yan +3 more
doaj +1 more source
Proceedings of the National Academy of Sciences of the United States of America, 2023 Significance Anti-CTLA-4 antibodies have revolutionized cancer treatment, but their mechanism of action is not well understood. Previous attempts to elucidate their mechanism have lacked a construct capable of intratumoral Treg depletion without CTLA-4 ...
B. M. Lax +11 more
semanticscholar +1 more source
Anti-PD-1 and anti-CTLA-4 treatment of iAST tumors.
, 2019 A, Treatment schedule: anti-PD-1 (10 mg/kg, i.p.) and anti-CTLA-4 (5 mg/kg, i.p.) therapy started at day 53 after virus injection and was applied in three doses at days 0, 3, and 7.
Veronika Schandl (6941093) +10 more
core +1 more source
, 2022 Supplementary Data from Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited ...
Andrew Sharabi (3158010) +15 more
core +1 more source
AI‐Designed Cyclic Peptides Enable Controllable Modulation of the CD28 Immune Checkpoint
Advanced Science, EarlyView.AI‐designed cyclic peptides enable controllable modulation of the CD28 immune checkpoint through reversible disruption of CD28‐CD80/CD86 interactions. The lead peptide, CIP‐3, suppresses T‐cell activation without intrinsic agonist activity, demonstrates dose‐dependent efficacy in a murine colitis model, and attenuates inflammatory cytokine production ...
Katarzyna Kuncewicz +4 more
wiley +1 more source